$4.98
-0.06-1.19%
Last update: 1:39 PM
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Applied Therapeutics (NASDAQ:APLT) Stock, Analyst Ratings, Price Targets, Forecasts
Applied Therapeutics Inc has a consensus price target of $10.04 based on the ratings of 7 analysts. The high is $14 issued by Baird on April 25, 2023. The low is $2.25 issued by Barclays on August 16, 2022. The 3 most-recent analyst ratings were released by RBC Capital on July 17, 2024, April 11, 2024, and March 26, 2024, respectively. With an average price target of $12 between RBC Capital, there's an implied 139.04% upside for Applied Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
UBS
Leerink Partners
Citigroup
Baird
1calculated from analyst ratings
Analyst Ratings for Applied Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/17/2024 | Buy Now | 139.04% | RBC Capital | Brian Abrahams | $12 → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 04/11/2024 | Buy Now | 139.04% | RBC Capital | Brian Abrahams | → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 03/26/2024 | Buy Now | 139.04% | RBC Capital | Brian Abrahams | → $12 | Initiates | → Outperform | Get Alert |
| 03/15/2024 | Buy Now | 158.96% | UBS | Esther Rajavelu | $12 → $13 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | 139.04% | UBS | Esther Rajavelu | $4 → $12 | Maintains | Buy | Get Alert |
| 02/22/2024 | Buy Now | 139.04% | Leerink Partners | Joseph Schwartz | → $12 | Initiates | → Outperform | Get Alert |
| 02/16/2024 | Buy Now | 39.44% | Citigroup | Yigal Nochomovitz | $5 → $7 | Maintains | Buy | Get Alert |
| 04/25/2023 | Buy Now | 178.88% | Baird | Brian Skorney | $18 → $14 | Maintains | Outperform | Get Alert |
| 04/05/2023 | Buy Now | -0.4% | Citigroup | Yigal Nochomovitz | $23 → $5 | Maintains | Buy | Get Alert |
| 08/17/2022 | Buy Now | 358.17% | Citigroup | Yigal Nochomovitz | $29 → $23 | Maintains | Buy | Get Alert |
| 08/16/2022 | Buy Now | -55.18% | Barclays | Carter Gould | $2.5 → $2.25 | Maintains | Equal-Weight | Get Alert |
| 05/20/2022 | Buy Now | 477.69% | Citigroup | Yigal Nochomovitz | $30 → $29 | Maintains | Buy | Get Alert |
| 03/21/2022 | Buy Now | -50.2% | Barclays | Carter Gould | $7 → $2.5 | Maintains | Equal-Weight | Get Alert |
| 01/04/2022 | Buy Now | 39.44% | Barclays | Carter Gould | $44 → $7 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 08/27/2021 | Buy Now | 99.2% | Goldman Sachs | Madhu Kumar | — | Downgrade | Neutral → Sell | Get Alert |
FAQ
What is the target price for Applied Therapeutics (APLT) stock?
The latest price target for Applied Therapeutics (NASDAQ:APLT) was reported by RBC Capital on July 17, 2024. The analyst firm set a price target for $12.00 expecting APLT to rise to within 12 months (a possible 140.96% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Applied Therapeutics (APLT)?
The latest analyst rating for Applied Therapeutics (NASDAQ:APLT) was provided by RBC Capital, and Applied Therapeutics reiterated their outperform rating.
When was the last upgrade for Applied Therapeutics (APLT)?
There is no last upgrade for Applied Therapeutics
When was the last downgrade for Applied Therapeutics (APLT)?
The last downgrade for Applied Therapeutics Inc happened on January 4, 2022 when Barclays changed their price target from $44 to $7 for Applied Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Applied Therapeutics (APLT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Applied Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Applied Therapeutics was filed on July 17, 2024 so you should expect the next rating to be made available sometime around July 17, 2025.
Is the Analyst Rating Applied Therapeutics (APLT) correct?
While ratings are subjective and will change, the latest Applied Therapeutics (APLT) rating was a reiterated with a price target of $12.00 to $12.00. The current price Applied Therapeutics (APLT) is trading at is $4.98, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.